CLINICAL EFFICACY OF REMICADE IN CBD

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 慢性铍病(CBD)是一种因吸入铍颗粒而引起的免疫系统疾病。暴露和疾病发生在使用铍和铍合金的工作场所，导致2%-6%的工人患病。泼尼松是治疗CBD最常用的处方药。停药通常会导致疾病症状的复发。重新开始类固醇治疗通常会改善患者的病情，然而，继续使用强的松可能会引起各种副作用。即使接受类固醇治疗，许多患者的病情仍在继续恶化。这种疗法可能会减缓疾病的临床进展，但通常不能阻止这种进展。在一些患者中，CBD对泼尼松或其他治疗没有反应，如果在中晚期被诊断出来，可能是致命的。因此，有必要测试治疗这种疾病的有前途的新疗法。这项研究旨在测试一种名为英夫利昔单抗的药物对CBD的临床疗效。这种药物可能会减少一种名为肿瘤坏死因子-α的物质，这种物质与更严重的疾病和肺部炎症有关。接受英夫利昔单抗可能有助于改善症状，并可能改善临床测试，如呼吸测试。基线和后续测试将寻找呼吸测试(肺功能测试)、肺部氧气交换(运动测试)、胸部X光和肺部炎症的改善情况。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic Beryllium Disease (CBD) is an immune system disorder caused by the inhalation of beryllium particles. Exposures and disease occurs in workplaces in which beryllium and beryllium alloys are used, producing disease in 2-6% of workers. Prednisone is the most commonly prescribed treatment for CBD. Cessation of the drug usually leads to relapse of the disease symptoms. Restarting steroid treatment usually improves the patient's condition, however, continual use of prednisone can cause a variety of side effects. Even with steroid treatment, many patients still continue to worsen. The treatment may slow the clinical progression of disease, but often does not halt that progression. In some patients CBD does not respond to prednisone or other therapy and can be fatal if diagnosed at intermediate or late stages. As such, there is a need to test promising new therapies for this disorder. This research study is designed to test the clinical effectiveness of a drug called infliximab in CBD. This drug may reduce a substance called TNF-alpha, which is associated with more severe disease and inflammation in the lung. Receiving infliximab may help with symptoms and may improve clinical testing, such as breathing tests. Baseline and follow up testing will look for improvements in breathing tests (Pulmonary Function Testing), exchange of oxygen in the lungs (exercise test), chest x-ray, and lung inflammation.